Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
INTRODUCTION. Lymphatic malformation is a rare malformation worldwide and is a concern for the parents of the infant; it is associated with aesthetic problems and possible deleterious effects due to obstruction or compression of vital organs. Sclerotherapy has been described as the best treatment option. OBJECTIVE. To determine the efficiency of bleomycin treatment in lymphangiomas in the pediatric population aged 0 to 18 years. MATERIALS AND METHODS. Retrospective analytical cross-sectional study. Population and known sample of 20 data from Electronic Medical Records of patients diagnosed with lymphangiomas and treated with bleomycin at the Carlos Andrade Marín Specialties Hospital, from January 2015 to January 2018. Inclusion criteria: patients aged 0 to 18 years with diagnosis of lymphangioma by ultrasound and computed angiotomography. Exclusion criteria: patients older than 18 years of age or diagnostic suspicion of lymphangioma without imaging studies, and/or who did not attend the control appointment, patients diagnosed with lymphangioma who did not receive bleomycin for treatment, children with other vascular malformations. Data analysis was performed in the statistical program International Business Machines Statistical Package for the Social Sciences. RESULTS. The median age in women was 6,25 years and 3,8 years in men. Ten patients were men. The average follow-up was 26,86 +/- 16,78 months. The average size of the lymphatic malformations was 5,77 +/- 3,73 cm. The most frequent location was cervical with 52,38%. Most were macronodular with 85,71%. The response was good or excellent in 81,00% of cases with the first infiltration and rose to 95,00% with the second and third, as required. CONCLUSION. The treatment of lymphangiomas with bleomycin was very effective in the population studied.
Fathy M, Elsayed AA. Intralesional Bleomycin Injection in Pediatric Lymphangioma, Is it the Magic Solution? SM J Pediatr Surg. 2018; 4(4):9-13. Available from: https://www.semanticscholar.org/paper/Intralesional-Bleomycin-Injection-in-Pediatric-Is-Fathy-Elsayed/4b9ed4b4960e38859be9d8bafe77288a47940e38
Regmi D, Bista M, Shrestha S, Shrestha D, Mahato NB. Comparative Study on Efficacy of Intralesional Bleomycin Injection in Head and Neck Lymphangioma and Vascular Malformation. J Clin Diagnostic Res. 2017; 11(12):11-3. DOI: 10.7860/JCDR/2017/34167.10945
Upadhyaya V, Bhatnagar A, Kumar B, Neyaz Z, Kishore JS, Sthapak E. Is multiple session of intralesional bleomycin mandatory for complete resolution of macrocystic lymphatic malformation? Indian J Plast Surg. 2018; 51(5):60-5. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992947/
Abdur-Rahman LO, Awolaran O, Nasir AA, Bamigbola KT, Abdulraheem NT, Oyinloye AO, et al. Efficacy of bleomycin for non-operative treatment of cervical lymphangioma in University of Ilorin Teaching Hospital, Nigeria. J Med Trop. 2017; 19:93-7. Available from: https://www.jmedtropics.org/article.asp?issn=2276-7096;year=2017;volume=19;issue=2;spage=93;epage=97;aulast=Abdur%2DRahman
Amodeo I, Cavallaro G, Raffaeli G, Colombo L, Fumagalli M, Cavalli R, et al. Abdominal cystic lymphangioma in a term newborn. Medicine (Baltimore). 2017; 96(8):1-5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569418/
Pan P. Ultrasound guided intralesional bleomycin therapy for cystic lymphangioma in childhood Ultrasound guided intralesional bleomycin therapy for cystic lymphangioma in childhood. Int J Contemp Pediatr. 2017; 4(4):1496-500. DOI: https://www.ijpediatrics.com/index.php/ijcp/article/view/913/794
Salinas VA, Fabre ES, Gomez HL, Fajardo GY, Argandoña WE. Eficacia de bleomicina como tratamiento esclerosante en linfangioma. Artículo Original. Rev Fac Cienc Med. 2018; 21(1):1-6. Disponible en: https://www.semanticscholar.org/paper/Eficacia-de-Bleomicina-como-tratamiento-en-Salinas-Parrales/fe51183216251a0cd136372fd81ba11cc5643462
Bilici S, Avci V, Öztaş T, Asena M, Çelik K. The Treatment of Lymphangiomas with Bleomycin in Childhood: A Retrospective Observational Study. Haydarpasa Numune Train Res Hosp Med J. 2019; 59(4):315-9. Available from: https://jag.journalagent.com/hnhjournal/pdfs/HNHJ-22590-RESEARCH_ARTICLE-BILICI.pdf
Rashi, Basu KS, Ganguly SS, Saha K, Ahmad S. Outcome and clinical efficacy of bleomycin and doxycycline percutaneous sclerotherapy for treatment of paediatric lymphatic malformations in a limited resource setting. Int J Contemp Pediatr. 2019; 6(4):1652-7. DOI: 10.18203/2349-3291.ijcp20192771
Gatea HK, Hassan MA, Abboud NJ. The role of intralesional bleomycin in the management of cutaneous infantile hemangioma. Iraqi Postgrad Med J. 2018; 17(3):204-11. Available from: https://iraqjournals.com/article_165531_f9028aedb27ebb82c79cbfdacbbc1ef8.pdf
Redkar RG, Chigicherla S, Joshi S, Bangar A, Tewari S. Efficacy of intralesional bleomycin as an alternative approach in the management of vascular anomalies. Saudi Surg J. 2017; 5:60-4. doi: 10.4103/ssj.ssj
Gallego Herrero C, Navarro Cutillas V. Tratamiento percutáneo de las malformaciones linfáticas en edad pediátrica: experiencia y resultados según el esclerosante empleado. Radiologia. 2017; 59(5):401-13. DOI: https://www.webcir.org/revistavirtual/articulos/2019/4_diciembre/Tratamiento%20percutaneo%20de%20las%20malformaciones%20linfaticas%20en%20edad%20pediatrica%20Radiologia%202017.pdf
Lerat J, Mounayer C, Scomparin A, Orsel S, Bessede J, Aubry K. Head and neck lymphatic malformation and treatment : Clinical study of 23 cases. Eur Ann Otorhinolaryngol Head Neck Dis. 2016; 133(6):393-6. Disponible en: http://dx.doi.org/10.1016/j.anorl.2016.07.004
Rahal MJH, Abou Al Ezz MR, El Hajj RA, Chokor JZ, Nasser SM, Moucharafieh RC. Elbow Cystic Lymphangioma in an 8-Month-Old Boy. Case Rep Orthop. 2019; 2019(Figure 5):1-5. DOI: 10.1155/2019/8762614
Rodríguez J, Cáceres F, Vargas P. Treatment of lymphangioma with OK-432 infiltration. Cirugía Pediátrica. 2012; 25(4):201-4. Available from: https://pubmed.ncbi.nlm.nih.gov/23659022/
Benga A, Zor F, Korkmaz A, Marinescu B, Gorantla V. Adipokine concentrations in lipoaspirates may have a role in wound healing. Indian J Plast Surg. 2017; 50(1):5-15. DOI: 10.4103/ijps.IJPS_103_16.
Rozman Z, Thambidorai R, Zaleha A, Zakaria Z, Zulfiqar M. Lymphangioma: Is intralesional bleomycin sclerotherapy effective? Biomed Imaging Interv J. 2011; 7(3):1-8. DOI: 10.2349/biij.7.3.e18
Amodeo I, Cavallaro G, Raffaeli G, Colombo L, Fumagalli M, Cavalli R, et al. Abdominal cystic lymphangioma in a term newborn. 2017 Feb; 96 (8): e5984. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569418/
Erikçi V, Hoşgör M, Yıldız M, Örnek Y, Aksoy N. Intralesional bleomycin sclerotherapy in childhood lymphangioma Intralesional bleomycin sclerotherapy in childhood lymphangioma. Turk J Pediatr. 2013 Jul-Aug; 55(4):396-400. Available from:https://pubmed.ncbi.nlm.nih.gov/24292033/
Wildgruber M, Sadick M, Müller-Wille R, Wohlgemuth WA. Vascular tumors in infants and adolescents. Insights Imaging. 2019; 10(1):6-8. DOI: 10.1186/s13244-019-0718-6
Wu HW, Wang X, Zheng JW, Zhao HG, Ge J, Zhang L, et al. Treatment of deep-seated facial microcystic lymphatic malformations with intralesional injection of pingyangmycin. Medicine (Baltimore). 2016; 95(37):e4790.
Miguelez SE, Gonzalez L, Monteagudo A, Mosca CO. Linfangioma en maxilar de un recién nacido: Reporte de un caso clínico. Rev Odontopediatría Latinoam. 2018; 8(1):83-92.
Hassan H, Abdelelah K. Management of cystic lymphangioma : experience of two referral centers. Ann Pediatr Surg. 2012; 8(4):123-8. DOI: 10.1097/01.XPS.0000418462.68421.e3
Ravi DK, Reddy JB. Intralesional Bleomycin for Lymphangioma : An Effective Alternative Non-surgical Therapy. Int J Sci Study. 2019; 6(10):82-3. Available from: https://www.ijss-sn.com/uploads/2/0/1/5/20153321/16_ijss_jan_oa16_-_2019.pdf
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.
